Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service Coverage

This publication has 14 references indexed in Scilit:

• Anti-VEGF Use for Conditions without US Food and Drug Administration Approval
  Ophthalmology Retina, 2025
• Twenty-Year Trends in Prevalence and Incidence of Diabetic Retinal Disease
  Ophthalmology, 2025
• High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare
  JAMA Health Forum, 2025
• Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
  Eye, 2024
• The Biosimilar Paradox
  Ophthalmology, 2023
• Improving Prior Authorization in Medicare Advantage
  JAMA, 2022
• Use of Bevacizumab Injections in Medicare Fee For Service in the IRIS® Registry
  Ophthalmology Retina, 2021
• Intravitreal Anti–Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use
  Ophthalmology, 2020
• Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients
  Ophthalmology, 2017
• Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
  New England Journal of Medicine, 2015